Central composite design for the development of carvedilol-loaded transdermal ethosomal hydrogel for extended and enhanced anti-hypertensive effect

Table 6 ANOVA of optimized quadratic model of the novel ethosomal formulation

Parameter	Source	DF	Sum of squares	Mean of squares	F Value	p Value
Y₁ (Vesicle size)	Model	9	2.051	2.279	99.65	< 0.0001
	Residual	10	22,866.43	2286.64
	Lack of fit	5	21,497.1	4299.42	15.69	0.0045
	Pure error	5	1369.33	273.87
Y₂ (% EE)	Model	9	5869.50	652.17	97.24	< 0.0001
	Residual	10	67.07	6.71
	Lack of fit	5	50.24	10.05	2.98	0.0029
	Pure error	5	16.83	3.37
Y₃ (% CDR)	Model	9	2090.19	232.24	31.76	< 0.0001
	Residual	10	73.13	7.31
	Lack of fit	5	16.61	3.32	0.29	0.0105
	Pure error	5	56.52	11.30